Relata®

Ruxolitinib

Product Information

  • Proprietary Name: Relata®
  • Generic Name: Ruxolitinib
  • Dosage Form: Tablet
  • Strengths: 5 mg, 10 mg, 15 mg, 20 mg
  • Indications: Myelofibrosis, Polycythemia Vera, Graft-versus-Host Disease (GvHD)

Oncology

Relata®

Ruxolitinib is indicated for the treatment of myelofibrosis, polycythemia vera, graft-versus-host disease (GvHD).

Ready to get started?

Curious about a specific position? Sign up for it.
© NanoAlvand. All rights reserved. Powered by ِDGN.